SALOFALK 1000 MG
MESALAZINE : 1000 MG · DIN 02242146 · ABBVIE CORPORATION
Health Canada status: MARKETED
What is SALOFALK?
SALOFALK 1000 MG contains MESALAZINE : 1000 MG. It is listed in the Health Canada Drug Product Database under DIN 02242146, held by ABBVIE CORPORATION, supplied as SUPPOSITORY for RECTAL administration. Health Canada currently lists it as marketed, status dated 28-Mar-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SALOFALK used for?
Management of ulcerative proctitis; adjunctive therapy in more extensive distal ulcerative colitis (DUC).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02242146 |
|---|---|
| Brand name | SALOFALK |
| Generic / active ingredient | MESALAZINE : 1000 MG |
| Manufacturer | ABBVIE CORPORATION |
| Strength | 1000 MG |
| Dosage form | SUPPOSITORY |
| Route of administration | RECTAL |
| Schedule | Prescription |
| ATC code | A07EC02 MESALAZINE |
| AHFS class | 90:28.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 28-Mar-2024 |
| Original market date | 2002-08-27 00:00:00 |
How is it administered?
Adults: 1.0 - 1.5 g/day. 500 mg 2-3 times daily or 1000 mg once daily at bedtime. Retain for 1-3 hours. Taper dose before discontinuation.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard section 11 header present but content truncated), though product is designed to melt at body temperature.
How is it supplied?
Strips of 6, boxes of 30 suppositories.
Contraindications
Hypersensitivity to mesalamine, salicylates, or components; severe renal impairment (GFR <30ml/min/1.73m2); severe hepatic impairment; gastric/duodenal ulcers; urinary tract obstructions.
Warnings and precautions
Renal impairment/interstitial nephritis; severe cutaneous reactions (SJS, TEN, DRESS); photosensitivity; acute intolerance syndrome; risk of myocarditis/pericarditis.
What can be used instead?
Other Canadian products sharing ATC code A07EC02 MESALAZINE. 18 of 29 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MEZAVANT | 1.2 G | TABLET (DELAYED AND EXTENDED RELEASE) | TAKEDA CANADA INC | MARKETED | DIN 02297558 |
| MEZERA | 1 G | SUPPOSITORY | AVIR PHARMA INC. | MARKETED | DIN 02474018 |
| MEZERA | 1 G | FOAM | AVIR PHARMA INC. | MARKETED | DIN 02474026 |
| MEZERA | 1 G | TABLET (DELAYED-RELEASE) | AVIR PHARMA INC. | MARKETED | DIN 02545012 |
| MEZERA | 500 MG | TABLET (DELAYED-RELEASE) | AVIR PHARMA INC. | MARKETED | DIN 02524481 |
| OCTASA | 1600 MG | TABLET (DELAYED-RELEASE) | TILLOTTS PHARMA AG | MARKETED | DIN 02529610 |
| OCTASA | 800 MG | TABLET (DELAYED-RELEASE) | TILLOTTS PHARMA AG | MARKETED | DIN 02465752 |
| PENTASA | 1 G | SUPPOSITORY | FERRING INC | MARKETED | DIN 02153564 |
| PENTASA | 1 G | TABLET (EXTENDED-RELEASE) | FERRING INC | MARKETED | DIN 02399466 |
| PENTASA | 1 G / 100 ML | SUSPENSION | FERRING INC | MARKETED | DIN 02153521 |
Who else supplies MESALAZINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. MESALAZINE appears in 884 registered pack listings across 11 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.